Cargando…
A role for CD47 in the development of experimental colitis mediated by SIRPα(+)CD103(−) dendritic cells
Mesenteric lymph node (mLN) CD103 (αE integrin)(+) dendritic cells (DCs) induce regulatory T cells and gut tolerance. However, the function of intestinal CD103(−) DCs remains to be clarified. CD47 is the ligand of signal regulatory protein α (SIRPα) and promotes SIRPα(+) myeloid cell migration. We f...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2737153/ https://www.ncbi.nlm.nih.gov/pubmed/19703989 http://dx.doi.org/10.1084/jem.20082805 |
Sumario: | Mesenteric lymph node (mLN) CD103 (αE integrin)(+) dendritic cells (DCs) induce regulatory T cells and gut tolerance. However, the function of intestinal CD103(−) DCs remains to be clarified. CD47 is the ligand of signal regulatory protein α (SIRPα) and promotes SIRPα(+) myeloid cell migration. We first show that mucosal CD103(−) DCs selectively express SIRPα and that their frequency was augmented in the lamina propria and mLNs of mice that developed Th17-biased colitis in response to trinitrobenzene sulfonic acid. In contrast, the percentage of SIRPα(+)CD103(−) DCs and Th17 responses were decreased in CD47-deficient (CD47 knockout [KO]) mice, which remained protected from colitis. We next demonstrate that transferring wild-type (WT), but not CD47 KO, SIRPα(+)CD103(−) DCs in CD47 KO mice elicited severe Th17-associated wasting disease. CD47 expression was required on the SIRPα(+)CD103(−) DCs for efficient trafficking to mLNs in vivo, whereas it was dispensable on both DCs and T cells for Th17 polarization in vitro. Finally, administration of a CD47-Fc molecule resulted in reduced SIRPα(+)CD103(−) DC–mediated Th17 responses and the protection of WT mice from colitis. We thus propose SIRPα(+)CD103(−) DCs as a pathogenic DC subset that drives Th17-biased responses and colitis, and the CD47–SIRPα axis as a potential therapeutic target for inflammatory bowel disease. |
---|